Global Heavy Menstrual Bleeding (HMB) Market By Diagnosis Type (Blood Tests, Pap Test, Endometrial Biopsy, Ultrasound, Sonohysterography, Hysteroscopy); By Offering (Products, Drugs & Therapies – Surgical Therapies: Dilation and Curettage (D&C), Uterine Artery Embolization, Focused Ultrasound Surgery, Myomectomy, Endometrial Ablation, Endometrial Resection, Hysterectomy, Non-Surgical Therapies: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Tranexamic Acid, Hormone-releasing Intrauterine Device (IUD), Oral Contraceptives, Oral Progesterone, Others, Menstrual Flow Tracking Applications); By Conditions (Endometrial Polyps, Polycystic Ovary Syndrome (PCOS), Salpingitis/ Pelvic Inflammatory Disease (PID), Ectopic Pregnancy, Uterine Fibroids, Cancer, Other Diseases and Conditions); By Distribution Channel (Online, Offline – Retail Pharmacies, Hospitals & Clinics, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Global heavy menstrual bleeding (HMB) market was is growing at an estimated CAGR of 22.3% over the forecast period. Despite being made from similar blood, flesh and bones, there are certain differences in a man and a woman. Those differences make women special. Menstruation is one of those differences, where women go through severe pain for every month until a certain time. Menstruation more commonly known as periods is the routine discharge of blood along with mucosal tissue that is located in the inner lining of the uterus via vagina. A normal cycle of menstruation of any women is completely dependent on her hormones. Though the discharge of blood is in normal amount, in some cases it may increase drastically causing complications where medical examination is needed. This is the reason why the global heavy menstrual bleeding (HMB) market is growing rapidly.
Diagnosis Type Outlook
On the basis of diagnosis type, the global heavy menstrual bleeding (HMB) market has been divided into blood tests, pap test, endometrial biopsy, ultrasound, sonohysterography and hysteroscopy. Blood tests and ultrasound are the most common and easiest way of diagnosing the root cause of any disease. While other ways of diagnosis are sought in case of major complications.
Offering Outlook
On the basis of offering, the global heavy menstrual bleeding (HMB) market has been segmented into products, drugs & therapies and menstrual flow tracking applications. The drugs & therapies segment is further divided into surgical therapies and non-surgical therapies. The surgical therapies segment comprises of dilation and curettage (D&C), uterine artery embolization, focused ultrasound surgery, myomectomy, endometrial ablation, endometrial resection and hysterectomy. Meanwhile the non-surgical therapies segment is bifurcated into nonsteroidal anti-inflammatory drugs (NSAIDs), tranexamic acid, hormone-releasing intrauterine Device (IUD), oral contraceptives, oral progesterone, and others.
Conditions Outlook
On the basis of conditions, the global heavy menstrual bleeding (HMB) market has been categorised into endometrial polyps, polycystic ovary syndrome (PCOS), salpingitis/ pelvic inflammatory disease (PID), ectopic pregnancy, uterine fibroids, cancer, and other diseases and conditions. Heavy bleeding is likely to be a symptom of having a cyst which can be cancerous and requires quick treatment. On the other hand, unhygienic health conditions can also cause severe infections.
Global Heavy Menstrual Bleeding (HMB) Market Revenue & Forecast, (US$ Million), 2022 – 2030
Distribution Channel Outlook
The distribution channel of the global heavy menstrual bleeding (HMB) market has been divided into online and offline. The offline segment is further bifurcated into retail pharmacies, hospitals & clinics, and others. The offline distribution channel accounts for maximum amount of revenue for this market as majority of people prefer getting treated from hospitals & clinics.
Region Outlook
On the basis of region, the global heavy menstrual bleeding (HMB) market has been divided into Latin America, Europe, North America, Asia-Pacific and others. The region of the North America dominates in terms of holding highest market share. Higher awareness about hygiene of private parts along with more open culture in terms of not considering menstrual cycle a taboo helps this market grow rampantly in the region.
Competitive Landscape
The report provides both, qualitative and quantitative research of global heavy menstrual bleeding (HMB) market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the major players operating in the global heavy menstrual bleeding (HMB) market are listed below:
- Bayer
- Ferring Pharmaceuticals
- Lannett
- LGM Pharma
- Myovan Sciences Ltd
- Neurocrine Biosciences, Inc.
- ObsEva
- Pfizer Inc.
- RAJVI ENTERPRISE
- Vibcare Pharma Pvt. Ltd
- Other Market Participants
Global Heavy Menstrual Bleeding (HMB) Market
By Type
- Blood Tests
- Pap Test
- Endometrial Biopsy
- Ultrasound
- Sonohysterography
- Hysteroscopy
By Offering
- Products
- Drugs
- Surgical Therapies
- Dilation and Curettage (D&C)
- Uterine Artery Embolization
- Focused Ultrasound Surgery
- Myomectomy
- Endometrial Ablation
- Endometrial Resection
- Hysterectomy
- Non-Surgical Therapies
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Tranexamic Acid
- Hormone-releasing Intrauterine Device (IUD)
- Oral Contraceptives
- Oral Progesterone
- Others
- Menstrual Flow Tracking Applications
- Surgical Therapies
By Conditions
- Endometrial Polyps
- Polycystic Ovary Syndrome (PCOS)
- Salpingitis/ Pelvic Inflammatory Diseases (PID)
- Ectopic Pregnancy
- Uterine Fibroids
- Cancer
- Other Diseases and Conditions
By Distribution Channel
- Online
- Offline
- Retail Pharmacies
- Hospitals & Clinics
- Others
By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 – 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Heavy Menstrual Bleeding (HMB) Market
6. Market Synopsis: Heavy Menstrual Bleeding (HMB) Market
7. Heavy Menstrual Bleeding (HMB) Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in Heavy Menstrual Bleeding (HMB) Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators: Heavy Menstrual Bleeding (HMB) Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Heavy Menstrual Bleeding (HMB) Market
8. Global Heavy Menstrual Bleeding (HMB) Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn)
8.2. Global Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
8.2.1. Blood Tests
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 – 2021
8.2.1.3. Market Forecast, 2022 – 2030
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market Estimation, 2015 – 2021
8.2.1.5.1.2. Market Forecast, 2022 – 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market Estimation, 2015 – 2021
8.2.1.5.2.2. Market Forecast, 2022 – 2030
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market Estimation, 2015 – 2021
8.2.1.5.3.2. Market Forecast, 2022 – 2030
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market Estimation, 2015 – 2021
8.2.1.5.4.2. Market Forecast, 2022 – 2030
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market Estimation, 2015 – 2021
8.2.1.5.5.2. Market Forecast, 2022 – 2030
8.2.2. Pap Test
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 – 2021
8.2.2.3. Market Forecast, 2022 – 2030
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market Estimation, 2015 – 2021
8.2.2.5.1.2. Market Forecast, 2022 – 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market Estimation, 2015 – 2021
8.2.2.5.2.2. Market Forecast, 2022 – 2030
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market Estimation, 2015 – 2021
8.2.2.5.3.2. Market Forecast, 2022 – 2030
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market Estimation, 2015 – 2021
8.2.2.5.4.2. Market Forecast, 2022 – 2030
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market Estimation, 2015 – 2021
8.2.2.5.5.2. Market Forecast, 2022 – 2030
8.2.3. Endometrial Biopsy
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 – 2021
8.2.3.3. Market Forecast, 2022 – 2030
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market Estimation, 2015 – 2021
8.2.3.5.1.2. Market Forecast, 2022 – 2030
8.2.3.5.2. Europe
8.2.3.5.2.1. Market Estimation, 2015 – 2021
8.2.3.5.2.2. Market Forecast, 2022 – 2030
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market Estimation, 2015 – 2021
8.2.3.5.3.2. Market Forecast, 2022 – 2030
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market Estimation, 2015 – 2021
8.2.3.5.4.2. Market Forecast, 2022 – 2030
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market Estimation, 2015 – 2021
8.2.3.5.5.2. Market Forecast, 2022 – 2030
8.2.4. Ultrasound
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 – 2021
8.2.4.3. Market Forecast, 2022 – 2030
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market Estimation, 2015 – 2021
8.2.4.5.1.2. Market Forecast, 2022 – 2030
8.2.4.5.2. Europe
8.2.4.5.2.1. Market Estimation, 2015 – 2021
8.2.4.5.2.2. Market Forecast, 2022 – 2030
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market Estimation, 2015 – 2021
8.2.4.5.3.2. Market Forecast, 2022 – 2030
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market Estimation, 2015 – 2021
8.2.4.5.4.2. Market Forecast, 2022 – 2030
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market Estimation, 2015 – 2021
8.2.4.5.5.2. Market Forecast, 2022 – 2030
8.2.5. Sonohysterography
8.2.5.1. Definition
8.2.5.2. Market Estimation and Penetration, 2015 – 2021
8.2.5.3. Market Forecast, 2022 – 2030
8.2.5.4. Compound Annual Growth Rate (CAGR)
8.2.5.5. Regional Bifurcation
8.2.5.5.1. North America
8.2.5.5.1.1. Market Estimation, 2015 – 2021
8.2.5.5.1.2. Market Forecast, 2022 – 2030
8.2.5.5.2. Europe
8.2.5.5.2.1. Market Estimation, 2015 – 2021
8.2.5.5.2.2. Market Forecast, 2022 – 2030
8.2.5.5.3. Asia Pacific
8.2.5.5.3.1. Market Estimation, 2015 – 2021
8.2.5.5.3.2. Market Forecast, 2022 – 2030
8.2.5.5.4. Middle East and Africa
8.2.5.5.4.1. Market Estimation, 2015 – 2021
8.2.5.5.4.2. Market Forecast, 2022 – 2030
8.2.5.5.5. Latin America
8.2.5.5.5.1. Market Estimation, 2015 – 2021
8.2.5.5.5.2. Market Forecast, 2022 – 2030
8.2.6. Hysteroscopy
8.2.6.1. Definition
8.2.6.2. Market Estimation and Penetration, 2015 – 2021
8.2.6.3. Market Forecast, 2022 – 2030
8.2.6.4. Compound Annual Growth Rate (CAGR)
8.2.6.5. Regional Bifurcation
8.2.6.5.1. North America
8.2.6.5.1.1. Market Estimation, 2015 – 2021
8.2.6.5.1.2. Market Forecast, 2022 – 2030
8.2.6.5.2. Europe
8.2.6.5.2.1. Market Estimation, 2015 – 2021
8.2.6.5.2.2. Market Forecast, 2022 – 2030
8.2.6.5.3. Asia Pacific
8.2.6.5.3.1. Market Estimation, 2015 – 2021
8.2.6.5.3.2. Market Forecast, 2022 – 2030
8.2.6.5.4. Middle East and Africa
8.2.6.5.4.1. Market Estimation, 2015 – 2021
8.2.6.5.4.2. Market Forecast, 2022 – 2030
8.2.6.5.5. Latin America
8.2.6.5.5.1. Market Estimation, 2015 – 2021
8.2.6.5.5.2. Market Forecast, 2022 – 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Diagnosis Type
9. Global Heavy Menstrual Bleeding (HMB) Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
9.2.1. Products
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 – 2021
9.2.1.3. Market Forecast, 2022 – 2030
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market Estimation, 2015 – 2021
9.2.1.5.1.2. Market Forecast, 2022 – 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market Estimation, 2015 – 2021
9.2.1.5.2.2. Market Forecast, 2022 – 2030
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market Estimation, 2015 – 2021
9.2.1.5.3.2. Market Forecast, 2022 – 2030
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market Estimation, 2015 – 2021
9.2.1.5.4.2. Market Forecast, 2022 – 2030
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market Estimation, 2015 – 2021
9.2.1.5.5.2. Market Forecast, 2022 – 2030
9.2.2. Drugs and Therapies (Definition, Market Estimation and Penetration, 2015 – 2021, Market Estimation (2015 – 2021), Market Forecast (2022 – 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Surgical Therapies, Non-Surgical Therapies)
9.2.2.1. Surgical Therapies
9.2.2.1.1. Dilation and Curettage (D and C)
9.2.2.1.2. Uterine Artery Embolization
9.2.2.1.3. Focused Ultrasound Surgery
9.2.2.1.4. Myomectomy
9.2.2.1.5. Endometrial Ablation
9.2.2.1.6. Endometrial Resection
9.2.2.1.7. Hysterectomy
9.2.2.2. Non-Surgical Therapies
9.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
9.2.2.2.2. Tranexamic Acid
9.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
9.2.2.2.4. Oral Contraceptives
9.2.2.2.5. Oral Progesterone
9.2.2.2.6. Others
9.2.3. Menstrual Flow Tracking Applications
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 – 2021
9.2.3.3. Market Forecast, 2022 – 2030
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market Estimation, 2015 – 2021
9.2.3.5.1.2. Market Forecast, 2022 – 2030
9.2.3.5.2. Europe
9.2.3.5.2.1. Market Estimation, 2015 – 2021
9.2.3.5.2.2. Market Forecast, 2022 – 2030
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market Estimation, 2015 – 2021
9.2.3.5.3.2. Market Forecast, 2022 – 2030
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market Estimation, 2015 – 2021
9.2.3.5.4.2. Market Forecast, 2022 – 2030
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market Estimation, 2015 – 2021
9.2.3.5.5.2. Market Forecast, 2022 – 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Offering
10. Global Heavy Menstrual Bleeding (HMB) Market Analysis and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
10.2.1. Endometrial Polyps
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 – 2021
10.2.1.3. Market Forecast, 2022 – 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015 – 2021
10.2.1.5.1.2. Market Forecast, 2022 – 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015 – 2021
10.2.1.5.2.2. Market Forecast, 2022 – 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 – 2021
10.2.1.5.3.2. Market Forecast, 2022 – 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 – 2021
10.2.1.5.4.2. Market Forecast, 2022 – 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015 – 2021
10.2.1.5.5.2. Market Forecast, 2022 – 2030
10.2.2. Polycystic Ovary Syndrome (PCOS)
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 – 2021
10.2.2.3. Market Forecast, 2022 – 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 – 2021
10.2.2.5.1.2. Market Forecast, 2022 – 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 – 2021
10.2.2.5.2.2. Market Forecast, 2022 – 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 – 2021
10.2.2.5.3.2. Market Forecast, 2022 – 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 – 2021
10.2.2.5.4.2. Market Forecast, 2022 – 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 – 2021
10.2.2.5.5.2. Market Forecast, 2022 – 2030
10.2.3. Salpingitis/Pelvic Inflammatory Disease (PID)
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 – 2021
10.2.3.3. Market Forecast, 2022 – 2030
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market Estimation, 2015 – 2021
10.2.3.5.1.2. Market Forecast, 2022 – 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market Estimation, 2015 – 2021
10.2.3.5.2.2. Market Forecast, 2022 – 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market Estimation, 2015 – 2021
10.2.3.5.3.2. Market Forecast, 2022 – 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market Estimation, 2015 – 2021
10.2.3.5.4.2. Market Forecast, 2022 – 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market Estimation, 2015 – 2021
10.2.3.5.5.2. Market Forecast, 2022 – 2030
10.2.4. Ectopic Pregnancy
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 – 2021
10.2.4.3. Market Forecast, 2022 – 2030
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market Estimation, 2015 – 2021
10.2.4.5.1.2. Market Forecast, 2022 – 2030
10.2.4.5.2. Europe
10.2.4.5.2.1. Market Estimation, 2015 – 2021
10.2.4.5.2.2. Market Forecast, 2022 – 2030
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market Estimation, 2015 – 2021
10.2.4.5.3.2. Market Forecast, 2022 – 2030
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market Estimation, 2015 – 2021
10.2.4.5.4.2. Market Forecast, 2022 – 2030
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market Estimation, 2015 – 2021
10.2.4.5.5.2. Market Forecast, 2022 – 2030
10.2.5. Uterine Fibroids
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 – 2021
10.2.5.3. Market Forecast, 2022 – 2030
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market Estimation, 2015 – 2021
10.2.5.5.1.2. Market Forecast, 2022 – 2030
10.2.5.5.2. Europe
10.2.5.5.2.1. Market Estimation, 2015 – 2021
10.2.5.5.2.2. Market Forecast, 2022 – 2030
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market Estimation, 2015 – 2021
10.2.5.5.3.2. Market Forecast, 2022 – 2030
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market Estimation, 2015 – 2021
10.2.5.5.4.2. Market Forecast, 2022 – 2030
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market Estimation, 2015 – 2021
10.2.5.5.5.2. Market Forecast, 2022 – 2030
10.2.6. Cancer
10.2.6.1. Definition
10.2.6.2. Market Estimation and Penetration, 2015 – 2021
10.2.6.3. Market Forecast, 2022 – 2030
10.2.6.4. Compound Annual Growth Rate (CAGR)
10.2.6.5. Regional Bifurcation
10.2.6.5.1. North America
10.2.6.5.1.1. Market Estimation, 2015 – 2021
10.2.6.5.1.2. Market Forecast, 2022 – 2030
10.2.6.5.2. Europe
10.2.6.5.2.1. Market Estimation, 2015 – 2021
10.2.6.5.2.2. Market Forecast, 2022 – 2030
10.2.6.5.3. Asia Pacific
10.2.6.5.3.1. Market Estimation, 2015 – 2021
10.2.6.5.3.2. Market Forecast, 2022 – 2030
10.2.6.5.4. Middle East and Africa
10.2.6.5.4.1. Market Estimation, 2015 – 2021
10.2.6.5.4.2. Market Forecast, 2022 – 2030
10.2.6.5.5. Latin America
10.2.6.5.5.1. Market Estimation, 2015 – 2021
10.2.6.5.5.2. Market Forecast, 2022 – 2030
10.2.7. Other Diseases and Conditions
10.2.7.1. Definition
10.2.7.2. Market Estimation and Penetration, 2015 – 2021
10.2.7.3. Market Forecast, 2022 – 2030
10.2.7.4. Compound Annual Growth Rate (CAGR)
10.2.7.5. Regional Bifurcation
10.2.7.5.1. North America
10.2.7.5.1.1. Market Estimation, 2015 – 2021
10.2.7.5.1.2. Market Forecast, 2022 – 2030
10.2.7.5.2. Europe
10.2.7.5.2.1. Market Estimation, 2015 – 2021
10.2.7.5.2.2. Market Forecast, 2022 – 2030
10.2.7.5.3. Asia Pacific
10.2.7.5.3.1. Market Estimation, 2015 – 2021
10.2.7.5.3.2. Market Forecast, 2022 – 2030
10.2.7.5.4. Middle East and Africa
10.2.7.5.4.1. Market Estimation, 2015 – 2021
10.2.7.5.4.2. Market Forecast, 2022 – 2030
10.2.7.5.5. Latin America
10.2.7.5.5.1. Market Estimation, 2015 – 2021
10.2.7.5.5.2. Market Forecast, 2022 – 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Conditions
11. Global Heavy Menstrual Bleeding (HMB) Market Analysis and Forecasts, 2022 – 2030
11.1. Overview
11.2. Global Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
11.2.1. Online
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 – 2021
11.2.1.3. Market Forecast, 2022 – 2030
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market Estimation, 2015 – 2021
11.2.1.5.1.2. Market Forecast, 2022 – 2030
11.2.1.5.2. Europe
11.2.1.5.2.1. Market Estimation, 2015 – 2021
11.2.1.5.2.2. Market Forecast, 2022 – 2030
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market Estimation, 2015 – 2021
11.2.1.5.3.2. Market Forecast, 2022 – 2030
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market Estimation, 2015 – 2021
11.2.1.5.4.2. Market Forecast, 2022 – 2030
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market Estimation, 2015 – 2021
11.2.1.5.5.2. Market Forecast, 2022 – 2030
11.2.2. Offline (Definition, Market Estimation and Penetration, 2015 – 2021, Market Estimation (2015 – 2021), Market Forecast (2022 – 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Retail Pharmacies, Hospitals and Clinics, Others)
11.2.2.1. Retail Pharmacies
11.2.2.2. Hospitals and Clinics
11.2.2.3. Others
11.3. Key Segment for Channeling Investments
11.3.1. By Distribution Channel
12. North America Heavy Menstrual Bleeding (HMB) Market Analysis and Forecasts, 2020 - 2028
12.1. Overview
12.1.1. North America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn)
12.2. North America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
12.2.1. Blood Tests
12.2.2. Pap Test
12.2.3. Endometrial Biopsy
12.2.4. Ultrasound
12.2.5. Sonohysterography
12.2.6. Hysteroscopy
12.3. North America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
12.3.1. Products
12.3.2. Drugs and Therapies
12.3.2.1. Surgical Therapies
12.3.2.1.1. Dilation and Curettage (D and C)
12.3.2.1.2. Uterine Artery Embolization
12.3.2.1.3. Focused Ultrasound Surgery
12.3.2.1.4. Myomectomy
12.3.2.1.5. Endometrial Ablation
12.3.2.1.6. Endometrial Resection
12.3.2.1.7. Hysterectomy
12.3.2.2. Non-Surgical Therapies
12.3.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
12.3.2.2.2. Tranexamic Acid
12.3.2.2.3. Hormone-releasing Intrauterine Device (IUD)
12.3.2.2.4. Oral Contraceptives
12.3.2.2.5. Oral Progesterone
12.3.2.2.6. Others
12.3.3. Menstrual Flow Tracking Applications
12.4. North America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
12.4.1. Endometrial Polyps
12.4.2. Polycystic Ovary Syndrome (PCOS)
12.4.3. Salpingitis/Pelvic Inflammatory Disease (PID)
12.4.4. Ectopic Pregnancy
12.4.5. Uterine Fibroids
12.4.6. Cancer
12.4.7. Other Diseases and Conditions
12.5. North America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.5.1. Online
12.5.2. Offline
12.5.2.1. Retail Pharmacies
12.5.2.2. Hospitals and Clinics
12.5.2.3. Others
12.6. North America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
12.6.1.1.1. Blood Tests
12.6.1.1.2. Pap Test
12.6.1.1.3. Endometrial Biopsy
12.6.1.1.4. Ultrasound
12.6.1.1.5. Sonohysterography
12.6.1.1.6. Hysteroscopy
12.6.1.2. U.S Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
12.6.1.2.1. Products
12.6.1.2.2. Drugs and Therapies
12.6.1.2.2.1. Surgical Therapies
12.6.1.2.2.1.1. Dilation and Curettage (D and C)
12.6.1.2.2.1.2. Uterine Artery Embolization
12.6.1.2.2.1.3. Focused Ultrasound Surgery
12.6.1.2.2.1.4. Myomectomy
12.6.1.2.2.1.5. Endometrial Ablation
12.6.1.2.2.1.6. Endometrial Resection
12.6.1.2.2.1.7. Hysterectomy
12.6.1.2.2.2. Non-Surgical Therapies
12.6.1.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
12.6.1.2.2.2.2. Tranexamic Acid
12.6.1.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
12.6.1.2.2.2.4. Oral Contraceptives
12.6.1.2.2.2.5. Oral Progesterone
12.6.1.2.2.2.6. Others
12.6.1.2.3. Menstrual Flow Tracking Applications
12.6.1.3. U.S Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
12.6.1.3.1. Endometrial Polyps
12.6.1.3.2. Polycystic Ovary Syndrome (PCOS)
12.6.1.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
12.6.1.3.4. Ectopic Pregnancy
12.6.1.3.5. Uterine Fibroids
12.6.1.3.6. Cancer
12.6.1.3.7. Other Diseases and Conditions
12.6.1.4. U.S Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.6.1.4.1. Online
12.6.1.4.2. Offline
12.6.1.4.2.1. Retail Pharmacies
12.6.1.4.2.2. Hospitals and Clinics
12.6.1.4.2.3. Others
12.6.2. Canada
12.6.2.1. Canada Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
12.6.2.1.1. Blood Tests
12.6.2.1.2. Pap Test
12.6.2.1.3. Endometrial Biopsy
12.6.2.1.4. Ultrasound
12.6.2.1.5. Sonohysterography
12.6.2.1.6. Hysteroscopy
12.6.2.2. Canada Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
12.6.2.2.1. Products
12.6.2.2.2. Drugs and Therapies
12.6.2.2.2.1. Surgical Therapies
12.6.2.2.2.1.1. Dilation and Curettage (D and C)
12.6.2.2.2.1.2. Uterine Artery Embolization
12.6.2.2.2.1.3. Focused Ultrasound Surgery
12.6.2.2.2.1.4. Myomectomy
12.6.2.2.2.1.5. Endometrial Ablation
12.6.2.2.2.1.6. Endometrial Resection
12.6.2.2.2.1.7. Hysterectomy
12.6.2.2.2.2. Non-Surgical Therapies
12.6.2.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
12.6.2.2.2.2.2. Tranexamic Acid
12.6.2.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
12.6.2.2.2.2.4. Oral Contraceptives
12.6.2.2.2.2.5. Oral Progesterone
12.6.2.2.2.2.6. Others
12.6.2.2.3. Menstrual Flow Tracking Applications
12.6.2.3. Canada Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
12.6.2.3.1. Endometrial Polyps
12.6.2.3.2. Polycystic Ovary Syndrome (PCOS)
12.6.2.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
12.6.2.3.4. Ectopic Pregnancy
12.6.2.3.5. Uterine Fibroids
12.6.2.3.6. Cancer
12.6.2.3.7. Other Diseases and Conditions
12.6.2.4. Canada Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.6.2.4.1. Online
12.6.2.4.2. Offline
12.6.2.4.2.1. Retail Pharmacies
12.6.2.4.2.2. Hospitals and Clinics
12.6.2.4.2.3. Others
12.6.3. Mexico
12.6.3.1. Mexico Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
12.6.3.1.1. Blood Tests
12.6.3.1.2. Pap Test
12.6.3.1.3. Endometrial Biopsy
12.6.3.1.4. Ultrasound
12.6.3.1.5. Sonohysterography
12.6.3.1.6. Hysteroscopy
12.6.3.2. Mexico Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
12.6.3.2.1. Products
12.6.3.2.2. Drugs and Therapies
12.6.3.2.2.1. Surgical Therapies
12.6.3.2.2.1.1. Dilation and Curettage (D and C)
12.6.3.2.2.1.2. Uterine Artery Embolization
12.6.3.2.2.1.3. Focused Ultrasound Surgery
12.6.3.2.2.1.4. Myomectomy
12.6.3.2.2.1.5. Endometrial Ablation
12.6.3.2.2.1.6. Endometrial Resection
12.6.3.2.2.1.7. Hysterectomy
12.6.3.2.2.2. Non-Surgical Therapies
12.6.3.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
12.6.3.2.2.2.2. Tranexamic Acid
12.6.3.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
12.6.3.2.2.2.4. Oral Contraceptives
12.6.3.2.2.2.5. Oral Progesterone
12.6.3.2.2.2.6. Others
12.6.3.2.3. Menstrual Flow Tracking Applications
12.6.3.3. Mexico Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
12.6.3.3.1. Endometrial Polyps
12.6.3.3.2. Polycystic Ovary Syndrome (PCOS)
12.6.3.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
12.6.3.3.4. Ectopic Pregnancy
12.6.3.3.5. Uterine Fibroids
12.6.3.3.6. Cancer
12.6.3.3.7. Other Diseases and Conditions
12.6.3.4. Mexico Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.6.3.4.1. Online
12.6.3.4.2. Offline
12.6.3.4.2.1. Retail Pharmacies
12.6.3.4.2.2. Hospitals and Clinics
12.6.3.4.2.3. Others
12.6.4. Rest of North America
12.6.4.1. Rest of North America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
12.6.4.1.1. Blood Tests
12.6.4.1.2. Pap Test
12.6.4.1.3. Endometrial Biopsy
12.6.4.1.4. Ultrasound
12.6.4.1.5. Sonohysterography
12.6.4.1.6. Hysteroscopy
12.6.4.2. Rest of North America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
12.6.4.2.1. Products
12.6.4.2.2. Drugs and Therapies
12.6.4.2.2.1. Surgical Therapies
12.6.4.2.2.1.1. Dilation and Curettage (D and C)
12.6.4.2.2.1.2. Uterine Artery Embolization
12.6.4.2.2.1.3. Focused Ultrasound Surgery
12.6.4.2.2.1.4. Myomectomy
12.6.4.2.2.1.5. Endometrial Ablation
12.6.4.2.2.1.6. Endometrial Resection
12.6.4.2.2.1.7. Hysterectomy
12.6.4.2.2.2. Non-Surgical Therapies
12.6.4.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
12.6.4.2.2.2.2. Tranexamic Acid
12.6.4.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
12.6.4.2.2.2.4. Oral Contraceptives
12.6.4.2.2.2.5. Oral Progesterone
12.6.4.2.2.2.6. Others
12.6.4.2.3. Menstrual Flow Tracking Applications
12.6.4.3. Rest of North America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
12.6.4.3.1. Endometrial Polyps
12.6.4.3.2. Polycystic Ovary Syndrome (PCOS)
12.6.4.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
12.6.4.3.4. Ectopic Pregnancy
12.6.4.3.5. Uterine Fibroids
12.6.4.3.6. Cancer
12.6.4.3.7. Other Diseases and Conditions
12.6.4.4. Rest of North America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.6.4.4.1. Online
12.6.4.4.2. Offline
12.6.4.4.2.1. Retail Pharmacies
12.6.4.4.2.2. Hospitals and Clinics
12.6.4.4.2.3. Others
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Diagnosis Type
12.7.3. By Offering
12.7.4. By Conditions
12.7.5. By Distribution Channel
13. Europe Heavy Menstrual Bleeding (HMB) Market Analysis and Forecasts, 2020 - 2028
13.1. Overview
13.1.1. Europe Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn)
13.2. Europe Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
13.2.1. Blood Tests
13.2.2. Pap Test
13.2.3. Endometrial Biopsy
13.2.4. Ultrasound
13.2.5. Sonohysterography
13.2.6. Hysteroscopy
13.3. Europe Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
13.3.1. Products
13.3.2. Drugs and Therapies
13.3.2.1. Surgical Therapies
13.3.2.1.1. Dilation and Curettage (D and C)
13.3.2.1.2. Uterine Artery Embolization
13.3.2.1.3. Focused Ultrasound Surgery
13.3.2.1.4. Myomectomy
13.3.2.1.5. Endometrial Ablation
13.3.2.1.6. Endometrial Resection
13.3.2.1.7. Hysterectomy
13.3.2.2. Non-Surgical Therapies
13.3.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
13.3.2.2.2. Tranexamic Acid
13.3.2.2.3. Hormone-releasing Intrauterine Device (IUD)
13.3.2.2.4. Oral Contraceptives
13.3.2.2.5. Oral Progesterone
13.3.2.2.6. Others
13.3.3. Menstrual Flow Tracking Applications
13.4. Europe Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
13.4.1. Endometrial Polyps
13.4.2. Polycystic Ovary Syndrome (PCOS)
13.4.3. Salpingitis/Pelvic Inflammatory Disease (PID)
13.4.4. Ectopic Pregnancy
13.4.5. Uterine Fibroids
13.4.6. Cancer
13.4.7. Other Diseases and Conditions
13.5. Europe Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.5.1. Online
13.5.2. Offline
13.5.2.1. Retail Pharmacies
13.5.2.2. Hospitals and Clinics
13.5.2.3. Others
13.6. Europe Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
13.6.1.1.1. Blood Tests
13.6.1.1.2. Pap Test
13.6.1.1.3. Endometrial Biopsy
13.6.1.1.4. Ultrasound
13.6.1.1.5. Sonohysterography
13.6.1.1.6. Hysteroscopy
13.6.1.2. France Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.1.2.1. Products
13.6.1.2.2. Drugs and Therapies
13.6.1.2.2.1. Surgical Therapies
13.6.1.2.2.1.1. Dilation and Curettage (D and C)
13.6.1.2.2.1.2. Uterine Artery Embolization
13.6.1.2.2.1.3. Focused Ultrasound Surgery
13.6.1.2.2.1.4. Myomectomy
13.6.1.2.2.1.5. Endometrial Ablation
13.6.1.2.2.1.6. Endometrial Resection
13.6.1.2.2.1.7. Hysterectomy
13.6.1.2.2.2. Non-Surgical Therapies
13.6.1.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
13.6.1.2.2.2.2. Tranexamic Acid
13.6.1.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
13.6.1.2.2.2.4. Oral Contraceptives
13.6.1.2.2.2.5. Oral Progesterone
13.6.1.2.2.2.6. Others
13.6.1.2.3. Menstrual Flow Tracking Applications
13.6.1.3. France Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
13.6.1.3.1. Endometrial Polyps
13.6.1.3.2. Polycystic Ovary Syndrome (PCOS)
13.6.1.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
13.6.1.3.4. Ectopic Pregnancy
13.6.1.3.5. Uterine Fibroids
13.6.1.3.6. Cancer
13.6.1.3.7. Other Diseases and Conditions
13.6.1.4. France Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.1.4.1. Online
13.6.1.4.2. Offline
13.6.1.4.2.1. Retail Pharmacies
13.6.1.4.2.2. Hospitals and Clinics
13.6.1.4.2.3. Others
13.6.2. The UK
13.6.2.1. The UK Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
13.6.2.1.1. Blood Tests
13.6.2.1.2. Pap Test
13.6.2.1.3. Endometrial Biopsy
13.6.2.1.4. Ultrasound
13.6.2.1.5. Sonohysterography
13.6.2.1.6. Hysteroscopy
13.6.2.2. The UK Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.2.2.1. Products
13.6.2.2.2. Drugs and Therapies
13.6.2.2.2.1. Surgical Therapies
13.6.2.2.2.1.1. Dilation and Curettage (D and C)
13.6.2.2.2.1.2. Uterine Artery Embolization
13.6.2.2.2.1.3. Focused Ultrasound Surgery
13.6.2.2.2.1.4. Myomectomy
13.6.2.2.2.1.5. Endometrial Ablation
13.6.2.2.2.1.6. Endometrial Resection
13.6.2.2.2.1.7. Hysterectomy
13.6.2.2.2.2. Non-Surgical Therapies
13.6.2.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
13.6.2.2.2.2.2. Tranexamic Acid
13.6.2.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
13.6.2.2.2.2.4. Oral Contraceptives
13.6.2.2.2.2.5. Oral Progesterone
13.6.2.2.2.2.6. Others
13.6.2.2.3. Menstrual Flow Tracking Applications
13.6.2.3. The UK Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
13.6.2.3.1. Endometrial Polyps
13.6.2.3.2. Polycystic Ovary Syndrome (PCOS)
13.6.2.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
13.6.2.3.4. Ectopic Pregnancy
13.6.2.3.5. Uterine Fibroids
13.6.2.3.6. Cancer
13.6.2.3.7. Other Diseases and Conditions
13.6.2.4. The UK Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.2.4.1. Online
13.6.2.4.2. Offline
13.6.2.4.2.1. Retail Pharmacies
13.6.2.4.2.2. Hospitals and Clinics
13.6.2.4.2.3. Others
13.6.3. Spain
13.6.3.1. Spain Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
13.6.3.1.1. Blood Tests
13.6.3.1.2. Pap Test
13.6.3.1.3. Endometrial Biopsy
13.6.3.1.4. Ultrasound
13.6.3.1.5. Sonohysterography
13.6.3.1.6. Hysteroscopy
13.6.3.2. Spain Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.3.2.1. Products
13.6.3.2.2. Drugs and Therapies
13.6.3.2.2.1. Surgical Therapies
13.6.3.2.2.1.1. Dilation and Curettage (D and C)
13.6.3.2.2.1.2. Uterine Artery Embolization
13.6.3.2.2.1.3. Focused Ultrasound Surgery
13.6.3.2.2.1.4. Myomectomy
13.6.3.2.2.1.5. Endometrial Ablation
13.6.3.2.2.1.6. Endometrial Resection
13.6.3.2.2.1.7. Hysterectomy
13.6.3.2.2.2. Non-Surgical Therapies
13.6.3.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
13.6.3.2.2.2.2. Tranexamic Acid
13.6.3.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
13.6.3.2.2.2.4. Oral Contraceptives
13.6.3.2.2.2.5. Oral Progesterone
13.6.3.2.2.2.6. Others
13.6.3.2.3. Menstrual Flow Tracking Applications
13.6.3.3. Spain Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
13.6.3.3.1. Endometrial Polyps
13.6.3.3.2. Polycystic Ovary Syndrome (PCOS)
13.6.3.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
13.6.3.3.4. Ectopic Pregnancy
13.6.3.3.5. Uterine Fibroids
13.6.3.3.6. Cancer
13.6.3.3.7. Other Diseases and Conditions
13.6.3.4. Spain Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.3.4.1. Online
13.6.3.4.2. Offline
13.6.3.4.2.1. Retail Pharmacies
13.6.3.4.2.2. Hospitals and Clinics
13.6.3.4.2.3. Others
13.6.4. Germany
13.6.4.1. Germany Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
13.6.4.1.1. Blood Tests
13.6.4.1.2. Pap Test
13.6.4.1.3. Endometrial Biopsy
13.6.4.1.4. Ultrasound
13.6.4.1.5. Sonohysterography
13.6.4.1.6. Hysteroscopy
13.6.4.2. Germany Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.4.2.1. Products
13.6.4.2.2. Drugs and Therapies
13.6.4.2.2.1. Surgical Therapies
13.6.4.2.2.1.1. Dilation and Curettage (D and C)
13.6.4.2.2.1.2. Uterine Artery Embolization
13.6.4.2.2.1.3. Focused Ultrasound Surgery
13.6.4.2.2.1.4. Myomectomy
13.6.4.2.2.1.5. Endometrial Ablation
13.6.4.2.2.1.6. Endometrial Resection
13.6.4.2.2.1.7. Hysterectomy
13.6.4.2.2.2. Non-Surgical Therapies
13.6.4.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
13.6.4.2.2.2.2. Tranexamic Acid
13.6.4.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
13.6.4.2.2.2.4. Oral Contraceptives
13.6.4.2.2.2.5. Oral Progesterone
13.6.4.2.2.2.6. Others
13.6.4.2.3. Menstrual Flow Tracking Applications
13.6.4.3. Germany Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
13.6.4.3.1. Endometrial Polyps
13.6.4.3.2. Polycystic Ovary Syndrome (PCOS)
13.6.4.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
13.6.4.3.4. Ectopic Pregnancy
13.6.4.3.5. Uterine Fibroids
13.6.4.3.6. Cancer
13.6.4.3.7. Other Diseases and Conditions
13.6.4.4. Germany Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.4.4.1. Online
13.6.4.4.2. Offline
13.6.4.4.2.1. Retail Pharmacies
13.6.4.4.2.2. Hospitals and Clinics
13.6.4.4.2.3. Others
13.6.5. Italy
13.6.5.1. Italy Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
13.6.5.1.1. Blood Tests
13.6.5.1.2. Pap Test
13.6.5.1.3. Endometrial Biopsy
13.6.5.1.4. Ultrasound
13.6.5.1.5. Sonohysterography
13.6.5.1.6. Hysteroscopy
13.6.5.2. Italy Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.5.2.1. Products
13.6.5.2.2. Drugs and Therapies
13.6.5.2.2.1. Surgical Therapies
13.6.5.2.2.1.1. Dilation and Curettage (D and C)
13.6.5.2.2.1.2. Uterine Artery Embolization
13.6.5.2.2.1.3. Focused Ultrasound Surgery
13.6.5.2.2.1.4. Myomectomy
13.6.5.2.2.1.5. Endometrial Ablation
13.6.5.2.2.1.6. Endometrial Resection
13.6.5.2.2.1.7. Hysterectomy
13.6.5.2.2.2. Non-Surgical Therapies
13.6.5.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
13.6.5.2.2.2.2. Tranexamic Acid
13.6.5.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
13.6.5.2.2.2.4. Oral Contraceptives
13.6.5.2.2.2.5. Oral Progesterone
13.6.5.2.2.2.6. Others
13.6.5.2.3. Menstrual Flow Tracking Applications
13.6.5.3. Italy Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
13.6.5.3.1. Endometrial Polyps
13.6.5.3.2. Polycystic Ovary Syndrome (PCOS)
13.6.5.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
13.6.5.3.4. Ectopic Pregnancy
13.6.5.3.5. Uterine Fibroids
13.6.5.3.6. Cancer
13.6.5.3.7. Other Diseases and Conditions
13.6.5.4. Italy Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.5.4.1. Online
13.6.5.4.2. Offline
13.6.5.4.2.1. Retail Pharmacies
13.6.5.4.2.2. Hospitals and Clinics
13.6.5.4.2.3. Others
13.6.6. Nordic Countries
13.6.6.1. Nordic Countries Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
13.6.6.1.1. Blood Tests
13.6.6.1.2. Pap Test
13.6.6.1.3. Endometrial Biopsy
13.6.6.1.4. Ultrasound
13.6.6.1.5. Sonohysterography
13.6.6.1.6. Hysteroscopy
13.6.6.2. Nordic Countries Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.6.2.1. Products
13.6.6.2.2. Drugs and Therapies
13.6.6.2.2.1. Surgical Therapies
13.6.6.2.2.1.1. Dilation and Curettage (D and C)
13.6.6.2.2.1.2. Uterine Artery Embolization
13.6.6.2.2.1.3. Focused Ultrasound Surgery
13.6.6.2.2.1.4. Myomectomy
13.6.6.2.2.1.5. Endometrial Ablation
13.6.6.2.2.1.6. Endometrial Resection
13.6.6.2.2.1.7. Hysterectomy
13.6.6.2.2.2. Non-Surgical Therapies
13.6.6.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
13.6.6.2.2.2.2. Tranexamic Acid
13.6.6.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
13.6.6.2.2.2.4. Oral Contraceptives
13.6.6.2.2.2.5. Oral Progesterone
13.6.6.2.2.2.6. Others
13.6.6.2.3. Menstrual Flow Tracking Applications
13.6.6.3. Nordic Countries Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
13.6.6.3.1. Endometrial Polyps
13.6.6.3.2. Polycystic Ovary Syndrome (PCOS)
13.6.6.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
13.6.6.3.4. Ectopic Pregnancy
13.6.6.3.5. Uterine Fibroids
13.6.6.3.6. Cancer
13.6.6.3.7. Other Diseases and Conditions
13.6.6.4. Nordic Countries Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.6.4.1. Online
13.6.6.4.2. Offline
13.6.6.4.2.1. Retail Pharmacies
13.6.6.4.2.2. Hospitals and Clinics
13.6.6.4.2.3. Others
13.6.6.5. Nordic Countries Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux Union
13.6.7.1. Benelux Union Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
13.6.7.1.1. Blood Tests
13.6.7.1.2. Pap Test
13.6.7.1.3. Endometrial Biopsy
13.6.7.1.4. Ultrasound
13.6.7.1.5. Sonohysterography
13.6.7.1.6. Hysteroscopy
13.6.7.2. Benelux Union Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.7.2.1. Products
13.6.7.2.2. Drugs and Therapies
13.6.7.2.2.1. Surgical Therapies
13.6.7.2.2.1.1. Dilation and Curettage (D and C)
13.6.7.2.2.1.2. Uterine Artery Embolization
13.6.7.2.2.1.3. Focused Ultrasound Surgery
13.6.7.2.2.1.4. Myomectomy
13.6.7.2.2.1.5. Endometrial Ablation
13.6.7.2.2.1.6. Endometrial Resection
13.6.7.2.2.1.7. Hysterectomy
13.6.7.2.2.2. Non-Surgical Therapies
13.6.7.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
13.6.7.2.2.2.2. Tranexamic Acid
13.6.7.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
13.6.7.2.2.2.4. Oral Contraceptives
13.6.7.2.2.2.5. Oral Progesterone
13.6.7.2.2.2.6. Others
13.6.7.2.3. Menstrual Flow Tracking Applications
13.6.7.3. Benelux Union Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
13.6.7.3.1. Endometrial Polyps
13.6.7.3.2. Polycystic Ovary Syndrome (PCOS)
13.6.7.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
13.6.7.3.4. Ectopic Pregnancy
13.6.7.3.5. Uterine Fibroids
13.6.7.3.6. Cancer
13.6.7.3.7. Other Diseases and Conditions
13.6.7.4. Benelux Union Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.7.4.1. Online
13.6.7.4.2. Offline
13.6.7.4.2.1. Retail Pharmacies
13.6.7.4.2.2. Hospitals and Clinics
13.6.7.4.2.3. Others
13.6.7.5. Benelux Union Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of Europe
13.6.8.1. Rest of Europe Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
13.6.8.1.1. Blood Tests
13.6.8.1.2. Pap Test
13.6.8.1.3. Endometrial Biopsy
13.6.8.1.4. Ultrasound
13.6.8.1.5. Sonohysterography
13.6.8.1.6. Hysteroscopy
13.6.8.2. Rest of Europe Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
13.6.8.2.1. Products
13.6.8.2.2. Drugs and Therapies
13.6.8.2.2.1. Surgical Therapies
13.6.8.2.2.1.1. Dilation and Curettage (D and C)
13.6.8.2.2.1.2. Uterine Artery Embolization
13.6.8.2.2.1.3. Focused Ultrasound Surgery
13.6.8.2.2.1.4. Myomectomy
13.6.8.2.2.1.5. Endometrial Ablation
13.6.8.2.2.1.6. Endometrial Resection
13.6.8.2.2.1.7. Hysterectomy
13.6.8.2.2.2. Non-Surgical Therapies
13.6.8.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
13.6.8.2.2.2.2. Tranexamic Acid
13.6.8.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
13.6.8.2.2.2.4. Oral Contraceptives
13.6.8.2.2.2.5. Oral Progesterone
13.6.8.2.2.2.6. Others
13.6.8.2.3. Menstrual Flow Tracking Applications
13.6.8.3. Rest of Europe Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
13.6.8.3.1. Endometrial Polyps
13.6.8.3.2. Polycystic Ovary Syndrome (PCOS)
13.6.8.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
13.6.8.3.4. Ectopic Pregnancy
13.6.8.3.5. Uterine Fibroids
13.6.8.3.6. Cancer
13.6.8.3.7. Other Diseases and Conditions
13.6.8.4. Rest of Europe Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.8.4.1. Online
13.6.8.4.2. Offline
13.6.8.4.2.1. Retail Pharmacies
13.6.8.4.2.2. Hospitals and Clinics
13.6.8.4.2.3. Others
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Diagnosis Type
13.7.3. By Offering
13.7.4. By Conditions
13.7.5. By Distribution Channel
14. Asia Pacific Heavy Menstrual Bleeding (HMB) Market Analysis and Forecasts, 2020 - 2028
14.1. Overview
14.1.1. Asia Pacific Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn)
14.2. Asia Pacific Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
14.2.1. Blood Tests
14.2.2. Pap Test
14.2.3. Endometrial Biopsy
14.2.4. Ultrasound
14.2.5. Sonohysterography
14.2.6. Hysteroscopy
14.3. Asia Pacific Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
14.3.1. Products
14.3.2. Drugs and Therapies
14.3.2.1. Surgical Therapies
14.3.2.1.1. Dilation and Curettage (D and C)
14.3.2.1.2. Uterine Artery Embolization
14.3.2.1.3. Focused Ultrasound Surgery
14.3.2.1.4. Myomectomy
14.3.2.1.5. Endometrial Ablation
14.3.2.1.6. Endometrial Resection
14.3.2.1.7. Hysterectomy
14.3.2.2. Non-Surgical Therapies
14.3.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
14.3.2.2.2. Tranexamic Acid
14.3.2.2.3. Hormone-releasing Intrauterine Device (IUD)
14.3.2.2.4. Oral Contraceptives
14.3.2.2.5. Oral Progesterone
14.3.2.2.6. Others
14.3.3. Menstrual Flow Tracking Applications
14.4. Asia Pacific Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
14.4.1. Endometrial Polyps
14.4.2. Polycystic Ovary Syndrome (PCOS)
14.4.3. Salpingitis/Pelvic Inflammatory Disease (PID)
14.4.4. Ectopic Pregnancy
14.4.5. Uterine Fibroids
14.4.6. Cancer
14.4.7. Other Diseases and Conditions
14.5. Asia Pacific Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.5.1. Online
14.5.2. Offline
14.5.2.1. Retail Pharmacies
14.5.2.2. Hospitals and Clinics
14.5.2.3. Others
14.6. Asia Pacific Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1. China Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
14.6.1.1.1. Blood Tests
14.6.1.1.2. Pap Test
14.6.1.1.3. Endometrial Biopsy
14.6.1.1.4. Ultrasound
14.6.1.1.5. Sonohysterography
14.6.1.1.6. Hysteroscopy
14.6.1.2. China Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
14.6.1.2.1. Products
14.6.1.2.2. Drugs and Therapies
14.6.1.2.2.1. Surgical Therapies
14.6.1.2.2.1.1. Dilation and Curettage (D and C)
14.6.1.2.2.1.2. Uterine Artery Embolization
14.6.1.2.2.1.3. Focused Ultrasound Surgery
14.6.1.2.2.1.4. Myomectomy
14.6.1.2.2.1.5. Endometrial Ablation
14.6.1.2.2.1.6. Endometrial Resection
14.6.1.2.2.1.7. Hysterectomy
14.6.1.2.2.2. Non-Surgical Therapies
14.6.1.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
14.6.1.2.2.2.2. Tranexamic Acid
14.6.1.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
14.6.1.2.2.2.4. Oral Contraceptives
14.6.1.2.2.2.5. Oral Progesterone
14.6.1.2.2.2.6. Others
14.6.1.2.3. Menstrual Flow Tracking Applications
14.6.1.3. China Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
14.6.1.3.1. Endometrial Polyps
14.6.1.3.2. Polycystic Ovary Syndrome (PCOS)
14.6.1.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
14.6.1.3.4. Ectopic Pregnancy
14.6.1.3.5. Uterine Fibroids
14.6.1.3.6. Cancer
14.6.1.3.7. Other Diseases and Conditions
14.6.1.4. China Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.6.1.4.1. Online
14.6.1.4.2. Offline
14.6.1.4.2.1. Retail Pharmacies
14.6.1.4.2.2. Hospitals and Clinics
14.6.1.4.2.3. Others
14.6.2. Japan
14.6.2.1. Japan Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
14.6.2.1.1. Blood Tests
14.6.2.1.2. Pap Test
14.6.2.1.3. Endometrial Biopsy
14.6.2.1.4. Ultrasound
14.6.2.1.5. Sonohysterography
14.6.2.1.6. Hysteroscopy
14.6.2.2. Japan Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
14.6.2.2.1. Products
14.6.2.2.2. Drugs and Therapies
14.6.2.2.2.1. Surgical Therapies
14.6.2.2.2.1.1. Dilation and Curettage (D and C)
14.6.2.2.2.1.2. Uterine Artery Embolization
14.6.2.2.2.1.3. Focused Ultrasound Surgery
14.6.2.2.2.1.4. Myomectomy
14.6.2.2.2.1.5. Endometrial Ablation
14.6.2.2.2.1.6. Endometrial Resection
14.6.2.2.2.1.7. Hysterectomy
14.6.2.2.2.2. Non-Surgical Therapies
14.6.2.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
14.6.2.2.2.2.2. Tranexamic Acid
14.6.2.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
14.6.2.2.2.2.4. Oral Contraceptives
14.6.2.2.2.2.5. Oral Progesterone
14.6.2.2.2.2.6. Others
14.6.2.2.3. Menstrual Flow Tracking Applications
14.6.2.3. Japan Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
14.6.2.3.1. Endometrial Polyps
14.6.2.3.2. Polycystic Ovary Syndrome (PCOS)
14.6.2.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
14.6.2.3.4. Ectopic Pregnancy
14.6.2.3.5. Uterine Fibroids
14.6.2.3.6. Cancer
14.6.2.3.7. Other Diseases and Conditions
14.6.2.4. Japan Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.6.2.4.1. Online
14.6.2.4.2. Offline
14.6.2.4.2.1. Retail Pharmacies
14.6.2.4.2.2. Hospitals and Clinics
14.6.2.4.2.3. Others
14.6.3. India
14.6.3.1. India Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
14.6.3.1.1. Blood Tests
14.6.3.1.2. Pap Test
14.6.3.1.3. Endometrial Biopsy
14.6.3.1.4. Ultrasound
14.6.3.1.5. Sonohysterography
14.6.3.1.6. Hysteroscopy
14.6.3.2. India Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
14.6.3.2.1. Products
14.6.3.2.2. Drugs and Therapies
14.6.3.2.2.1. Surgical Therapies
14.6.3.2.2.1.1. Dilation and Curettage (D and C)
14.6.3.2.2.1.2. Uterine Artery Embolization
14.6.3.2.2.1.3. Focused Ultrasound Surgery
14.6.3.2.2.1.4. Myomectomy
14.6.3.2.2.1.5. Endometrial Ablation
14.6.3.2.2.1.6. Endometrial Resection
14.6.3.2.2.1.7. Hysterectomy
14.6.3.2.2.2. Non-Surgical Therapies
14.6.3.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
14.6.3.2.2.2.2. Tranexamic Acid
14.6.3.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
14.6.3.2.2.2.4. Oral Contraceptives
14.6.3.2.2.2.5. Oral Progesterone
14.6.3.2.2.2.6. Others
14.6.3.2.3. Menstrual Flow Tracking Applications
14.6.3.3. India Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
14.6.3.3.1. Endometrial Polyps
14.6.3.3.2. Polycystic Ovary Syndrome (PCOS)
14.6.3.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
14.6.3.3.4. Ectopic Pregnancy
14.6.3.3.5. Uterine Fibroids
14.6.3.3.6. Cancer
14.6.3.3.7. Other Diseases and Conditions
14.6.3.4. India Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.6.3.4.1. Online
14.6.3.4.2. Offline
14.6.3.4.2.1. Retail Pharmacies
14.6.3.4.2.2. Hospitals and Clinics
14.6.3.4.2.3. Others
14.6.4. New Zealand
14.6.4.1. New Zealand Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
14.6.4.1.1. Blood Tests
14.6.4.1.2. Pap Test
14.6.4.1.3. Endometrial Biopsy
14.6.4.1.4. Ultrasound
14.6.4.1.5. Sonohysterography
14.6.4.1.6. Hysteroscopy
14.6.4.2. New Zealand Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
14.6.4.2.1. Products
14.6.4.2.2. Drugs and Therapies
14.6.4.2.2.1. Surgical Therapies
14.6.4.2.2.1.1. Dilation and Curettage (D and C)
14.6.4.2.2.1.2. Uterine Artery Embolization
14.6.4.2.2.1.3. Focused Ultrasound Surgery
14.6.4.2.2.1.4. Myomectomy
14.6.4.2.2.1.5. Endometrial Ablation
14.6.4.2.2.1.6. Endometrial Resection
14.6.4.2.2.1.7. Hysterectomy
14.6.4.2.2.2. Non-Surgical Therapies
14.6.4.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
14.6.4.2.2.2.2. Tranexamic Acid
14.6.4.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
14.6.4.2.2.2.4. Oral Contraceptives
14.6.4.2.2.2.5. Oral Progesterone
14.6.4.2.2.2.6. Others
14.6.4.2.3. Menstrual Flow Tracking Applications
14.6.4.3. New Zealand Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
14.6.4.3.1. Endometrial Polyps
14.6.4.3.2. Polycystic Ovary Syndrome (PCOS)
14.6.4.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
14.6.4.3.4. Ectopic Pregnancy
14.6.4.3.5. Uterine Fibroids
14.6.4.3.6. Cancer
14.6.4.3.7. Other Diseases and Conditions
14.6.4.4. New Zealand Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.6.4.4.1. Online
14.6.4.4.2. Offline
14.6.4.4.2.1. Retail Pharmacies
14.6.4.4.2.2. Hospitals and Clinics
14.6.4.4.2.3. Others
14.6.5. Australia
14.6.5.1. Australia Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
14.6.5.1.1. Blood Tests
14.6.5.1.2. Pap Test
14.6.5.1.3. Endometrial Biopsy
14.6.5.1.4. Ultrasound
14.6.5.1.5. Sonohysterography
14.6.5.1.6. Hysteroscopy
14.6.5.2. Australia Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
14.6.5.2.1. Products
14.6.5.2.2. Drugs and Therapies
14.6.5.2.2.1. Surgical Therapies
14.6.5.2.2.1.1. Dilation and Curettage (D and C)
14.6.5.2.2.1.2. Uterine Artery Embolization
14.6.5.2.2.1.3. Focused Ultrasound Surgery
14.6.5.2.2.1.4. Myomectomy
14.6.5.2.2.1.5. Endometrial Ablation
14.6.5.2.2.1.6. Endometrial Resection
14.6.5.2.2.1.7. Hysterectomy
14.6.5.2.2.2. Non-Surgical Therapies
14.6.5.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
14.6.5.2.2.2.2. Tranexamic Acid
14.6.5.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
14.6.5.2.2.2.4. Oral Contraceptives
14.6.5.2.2.2.5. Oral Progesterone
14.6.5.2.2.2.6. Others
14.6.5.2.3. Menstrual Flow Tracking Applications
14.6.5.3. Australia Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
14.6.5.3.1. Endometrial Polyps
14.6.5.3.2. Polycystic Ovary Syndrome (PCOS)
14.6.5.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
14.6.5.3.4. Ectopic Pregnancy
14.6.5.3.5. Uterine Fibroids
14.6.5.3.6. Cancer
14.6.5.3.7. Other Diseases and Conditions
14.6.5.4. Australia Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.6.5.4.1. Online
14.6.5.4.2. Offline
14.6.5.4.2.1. Retail Pharmacies
14.6.5.4.2.2. Hospitals and Clinics
14.6.5.4.2.3. Others
14.6.6. South Korea
14.6.6.1. South Korea Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
14.6.6.1.1. Blood Tests
14.6.6.1.2. Pap Test
14.6.6.1.3. Endometrial Biopsy
14.6.6.1.4. Ultrasound
14.6.6.1.5. Sonohysterography
14.6.6.1.6. Hysteroscopy
14.6.6.2. South Korea Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
14.6.6.2.1. Products
14.6.6.2.2. Drugs and Therapies
14.6.6.2.2.1. Surgical Therapies
14.6.6.2.2.1.1. Dilation and Curettage (D and C)
14.6.6.2.2.1.2. Uterine Artery Embolization
14.6.6.2.2.1.3. Focused Ultrasound Surgery
14.6.6.2.2.1.4. Myomectomy
14.6.6.2.2.1.5. Endometrial Ablation
14.6.6.2.2.1.6. Endometrial Resection
14.6.6.2.2.1.7. Hysterectomy
14.6.6.2.2.2. Non-Surgical Therapies
14.6.6.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
14.6.6.2.2.2.2. Tranexamic Acid
14.6.6.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
14.6.6.2.2.2.4. Oral Contraceptives
14.6.6.2.2.2.5. Oral Progesterone
14.6.6.2.2.2.6. Others
14.6.6.2.3. Menstrual Flow Tracking Applications
14.6.6.3. South Korea Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
14.6.6.3.1. Endometrial Polyps
14.6.6.3.2. Polycystic Ovary Syndrome (PCOS)
14.6.6.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
14.6.6.3.4. Ectopic Pregnancy
14.6.6.3.5. Uterine Fibroids
14.6.6.3.6. Cancer
14.6.6.3.7. Other Diseases and Conditions
14.6.6.4. South Korea Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.6.6.4.1. Online
14.6.6.4.2. Offline
14.6.6.4.2.1. Retail Pharmacies
14.6.6.4.2.2. Hospitals and Clinics
14.6.6.4.2.3. Others
14.6.7. Southeast Asia
14.6.7.1. Southeast Asia Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
14.6.7.1.1. Blood Tests
14.6.7.1.2. Pap Test
14.6.7.1.3. Endometrial Biopsy
14.6.7.1.4. Ultrasound
14.6.7.1.5. Sonohysterography
14.6.7.1.6. Hysteroscopy
14.6.7.2. Southeast Asia Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
14.6.7.2.1. Products
14.6.7.2.2. Drugs and Therapies
14.6.7.2.2.1. Surgical Therapies
14.6.7.2.2.1.1. Dilation and Curettage (D and C)
14.6.7.2.2.1.2. Uterine Artery Embolization
14.6.7.2.2.1.3. Focused Ultrasound Surgery
14.6.7.2.2.1.4. Myomectomy
14.6.7.2.2.1.5. Endometrial Ablation
14.6.7.2.2.1.6. Endometrial Resection
14.6.7.2.2.1.7. Hysterectomy
14.6.7.2.2.2. Non-Surgical Therapies
14.6.7.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
14.6.7.2.2.2.2. Tranexamic Acid
14.6.7.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
14.6.7.2.2.2.4. Oral Contraceptives
14.6.7.2.2.2.5. Oral Progesterone
14.6.7.2.2.2.6. Others
14.6.7.2.3. Menstrual Flow Tracking Applications
14.6.7.3. Southeast Asia Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
14.6.7.3.1. Endometrial Polyps
14.6.7.3.2. Polycystic Ovary Syndrome (PCOS)
14.6.7.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
14.6.7.3.4. Ectopic Pregnancy
14.6.7.3.5. Uterine Fibroids
14.6.7.3.6. Cancer
14.6.7.3.7. Other Diseases and Conditions
14.6.7.4. Southeast Asia Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.6.7.4.1. Online
14.6.7.4.2. Offline
14.6.7.4.2.1. Retail Pharmacies
14.6.7.4.2.2. Hospitals and Clinics
14.6.7.4.2.3. Others
14.6.7.5. Southeast Asia Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1. Rest of Asia Pacific Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
14.6.8.1.1. Blood Tests
14.6.8.1.2. Pap Test
14.6.8.1.3. Endometrial Biopsy
14.6.8.1.4. Ultrasound
14.6.8.1.5. Sonohysterography
14.6.8.1.6. Hysteroscopy
14.6.8.2. Rest of Asia Pacific Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
14.6.8.2.1. Products
14.6.8.2.2. Drugs and Therapies
14.6.8.2.2.1. Surgical Therapies
14.6.8.2.2.1.1. Dilation and Curettage (D and C)
14.6.8.2.2.1.2. Uterine Artery Embolization
14.6.8.2.2.1.3. Focused Ultrasound Surgery
14.6.8.2.2.1.4. Myomectomy
14.6.8.2.2.1.5. Endometrial Ablation
14.6.8.2.2.1.6. Endometrial Resection
14.6.8.2.2.1.7. Hysterectomy
14.6.8.2.2.2. Non-Surgical Therapies
14.6.8.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
14.6.8.2.2.2.2. Tranexamic Acid
14.6.8.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
14.6.8.2.2.2.4. Oral Contraceptives
14.6.8.2.2.2.5. Oral Progesterone
14.6.8.2.2.2.6. Others
14.6.8.2.3. Menstrual Flow Tracking Applications
14.6.8.3. Rest of Asia Pacific Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
14.6.8.3.1. Endometrial Polyps
14.6.8.3.2. Polycystic Ovary Syndrome (PCOS)
14.6.8.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
14.6.8.3.4. Ectopic Pregnancy
14.6.8.3.5. Uterine Fibroids
14.6.8.3.6. Cancer
14.6.8.3.7. Other Diseases and Conditions
14.6.8.4. Rest of Asia Pacific Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.6.8.4.1. Online
14.6.8.4.2. Offline
14.6.8.4.2.1. Retail Pharmacies
14.6.8.4.2.2. Hospitals and Clinics
14.6.8.4.2.3. Others
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Diagnosis Type
14.7.3. By Offering
14.7.4. By Conditions
14.7.5. By Distribution Channel
15. Middle East and Africa Heavy Menstrual Bleeding (HMB) Market Analysis and Forecasts, 2020 - 2028
15.1. Overview
15.1.1. Middle East and Africa Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn)
15.2. Middle East and Africa Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
15.2.1. Blood Tests
15.2.2. Pap Test
15.2.3. Endometrial Biopsy
15.2.4. Ultrasound
15.2.5. Sonohysterography
15.2.6. Hysteroscopy
15.3. Middle East and Africa Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
15.3.1. Products
15.3.2. Drugs and Therapies
15.3.2.1. Surgical Therapies
15.3.2.1.1. Dilation and Curettage (D and C)
15.3.2.1.2. Uterine Artery Embolization
15.3.2.1.3. Focused Ultrasound Surgery
15.3.2.1.4. Myomectomy
15.3.2.1.5. Endometrial Ablation
15.3.2.1.6. Endometrial Resection
15.3.2.1.7. Hysterectomy
15.3.2.2. Non-Surgical Therapies
15.3.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
15.3.2.2.2. Tranexamic Acid
15.3.2.2.3. Hormone-releasing Intrauterine Device (IUD)
15.3.2.2.4. Oral Contraceptives
15.3.2.2.5. Oral Progesterone
15.3.2.2.6. Others
15.3.3. Menstrual Flow Tracking Applications
15.4. Middle East and Africa Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
15.4.1. Endometrial Polyps
15.4.2. Polycystic Ovary Syndrome (PCOS)
15.4.3. Salpingitis/Pelvic Inflammatory Disease (PID)
15.4.4. Ectopic Pregnancy
15.4.5. Uterine Fibroids
15.4.6. Cancer
15.4.7. Other Diseases and Conditions
15.5. Middle East and Africa Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.5.1. Online
15.5.2. Offline
15.5.2.1. Retail Pharmacies
15.5.2.2. Hospitals and Clinics
15.5.2.3. Others
15.6. Middle East and Africa Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1. Saudi Arabia Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
15.6.1.1.1. Blood Tests
15.6.1.1.2. Pap Test
15.6.1.1.3. Endometrial Biopsy
15.6.1.1.4. Ultrasound
15.6.1.1.5. Sonohysterography
15.6.1.1.6. Hysteroscopy
15.6.1.2. Saudi Arabia Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
15.6.1.2.1. Products
15.6.1.2.2. Drugs and Therapies
15.6.1.2.2.1. Surgical Therapies
15.6.1.2.2.1.1. Dilation and Curettage (D and C)
15.6.1.2.2.1.2. Uterine Artery Embolization
15.6.1.2.2.1.3. Focused Ultrasound Surgery
15.6.1.2.2.1.4. Myomectomy
15.6.1.2.2.1.5. Endometrial Ablation
15.6.1.2.2.1.6. Endometrial Resection
15.6.1.2.2.1.7. Hysterectomy
15.6.1.2.2.2. Non-Surgical Therapies
15.6.1.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
15.6.1.2.2.2.2. Tranexamic Acid
15.6.1.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
15.6.1.2.2.2.4. Oral Contraceptives
15.6.1.2.2.2.5. Oral Progesterone
15.6.1.2.2.2.6. Others
15.6.1.2.3. Menstrual Flow Tracking Applications
15.6.1.3. Saudi Arabia Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
15.6.1.3.1. Endometrial Polyps
15.6.1.3.2. Polycystic Ovary Syndrome (PCOS)
15.6.1.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
15.6.1.3.4. Ectopic Pregnancy
15.6.1.3.5. Uterine Fibroids
15.6.1.3.6. Cancer
15.6.1.3.7. Other Diseases and Conditions
15.6.1.4. Saudi Arabia Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.6.1.4.1. Online
15.6.1.4.2. Offline
15.6.1.4.2.1. Retail Pharmacies
15.6.1.4.2.2. Hospitals and Clinics
15.6.1.4.2.3. Others
15.6.2. UAE
15.6.2.1. UAE Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
15.6.2.1.1. Blood Tests
15.6.2.1.2. Pap Test
15.6.2.1.3. Endometrial Biopsy
15.6.2.1.4. Ultrasound
15.6.2.1.5. Sonohysterography
15.6.2.1.6. Hysteroscopy
15.6.2.2. UAE Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
15.6.2.2.1. Products
15.6.2.2.2. Drugs and Therapies
15.6.2.2.2.1. Surgical Therapies
15.6.2.2.2.1.1. Dilation and Curettage (D and C)
15.6.2.2.2.1.2. Uterine Artery Embolization
15.6.2.2.2.1.3. Focused Ultrasound Surgery
15.6.2.2.2.1.4. Myomectomy
15.6.2.2.2.1.5. Endometrial Ablation
15.6.2.2.2.1.6. Endometrial Resection
15.6.2.2.2.1.7. Hysterectomy
15.6.2.2.2.2. Non-Surgical Therapies
15.6.2.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
15.6.2.2.2.2.2. Tranexamic Acid
15.6.2.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
15.6.2.2.2.2.4. Oral Contraceptives
15.6.2.2.2.2.5. Oral Progesterone
15.6.2.2.2.2.6. Others
15.6.2.2.3. Menstrual Flow Tracking Applications
15.6.2.3. UAE Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
15.6.2.3.1. Endometrial Polyps
15.6.2.3.2. Polycystic Ovary Syndrome (PCOS)
15.6.2.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
15.6.2.3.4. Ectopic Pregnancy
15.6.2.3.5. Uterine Fibroids
15.6.2.3.6. Cancer
15.6.2.3.7. Other Diseases and Conditions
15.6.2.4. UAE Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.6.2.4.1. Online
15.6.2.4.2. Offline
15.6.2.4.2.1. Retail Pharmacies
15.6.2.4.2.2. Hospitals and Clinics
15.6.2.4.2.3. Others
15.6.3. Egypt
15.6.3.1. Egypt Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
15.6.3.1.1. Blood Tests
15.6.3.1.2. Pap Test
15.6.3.1.3. Endometrial Biopsy
15.6.3.1.4. Ultrasound
15.6.3.1.5. Sonohysterography
15.6.3.1.6. Hysteroscopy
15.6.3.2. Egypt Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
15.6.3.2.1. Products
15.6.3.2.2. Drugs and Therapies
15.6.3.2.2.1. Surgical Therapies
15.6.3.2.2.1.1. Dilation and Curettage (D and C)
15.6.3.2.2.1.2. Uterine Artery Embolization
15.6.3.2.2.1.3. Focused Ultrasound Surgery
15.6.3.2.2.1.4. Myomectomy
15.6.3.2.2.1.5. Endometrial Ablation
15.6.3.2.2.1.6. Endometrial Resection
15.6.3.2.2.1.7. Hysterectomy
15.6.3.2.2.2. Non-Surgical Therapies
15.6.3.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
15.6.3.2.2.2.2. Tranexamic Acid
15.6.3.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
15.6.3.2.2.2.4. Oral Contraceptives
15.6.3.2.2.2.5. Oral Progesterone
15.6.3.2.2.2.6. Others
15.6.3.2.3. Menstrual Flow Tracking Applications
15.6.3.3. Egypt Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
15.6.3.3.1. Endometrial Polyps
15.6.3.3.2. Polycystic Ovary Syndrome (PCOS)
15.6.3.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
15.6.3.3.4. Ectopic Pregnancy
15.6.3.3.5. Uterine Fibroids
15.6.3.3.6. Cancer
15.6.3.3.7. Other Diseases and Conditions
15.6.3.4. Egypt Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.6.3.4.1. Online
15.6.3.4.2. Offline
15.6.3.4.2.1. Retail Pharmacies
15.6.3.4.2.2. Hospitals and Clinics
15.6.3.4.2.3. Others
15.6.4. Kuwait
15.6.4.1. Kuwait Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
15.6.4.1.1. Blood Tests
15.6.4.1.2. Pap Test
15.6.4.1.3. Endometrial Biopsy
15.6.4.1.4. Ultrasound
15.6.4.1.5. Sonohysterography
15.6.4.1.6. Hysteroscopy
15.6.4.2. Kuwait Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
15.6.4.2.1. Products
15.6.4.2.2. Drugs and Therapies
15.6.4.2.2.1. Surgical Therapies
15.6.4.2.2.1.1. Dilation and Curettage (D and C)
15.6.4.2.2.1.2. Uterine Artery Embolization
15.6.4.2.2.1.3. Focused Ultrasound Surgery
15.6.4.2.2.1.4. Myomectomy
15.6.4.2.2.1.5. Endometrial Ablation
15.6.4.2.2.1.6. Endometrial Resection
15.6.4.2.2.1.7. Hysterectomy
15.6.4.2.2.2. Non-Surgical Therapies
15.6.4.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
15.6.4.2.2.2.2. Tranexamic Acid
15.6.4.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
15.6.4.2.2.2.4. Oral Contraceptives
15.6.4.2.2.2.5. Oral Progesterone
15.6.4.2.2.2.6. Others
15.6.4.2.3. Menstrual Flow Tracking Applications
15.6.4.3. Kuwait Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
15.6.4.3.1. Endometrial Polyps
15.6.4.3.2. Polycystic Ovary Syndrome (PCOS)
15.6.4.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
15.6.4.3.4. Ectopic Pregnancy
15.6.4.3.5. Uterine Fibroids
15.6.4.3.6. Cancer
15.6.4.3.7. Other Diseases and Conditions
15.6.4.4. Kuwait Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.6.4.4.1. Online
15.6.4.4.2. Offline
15.6.4.4.2.1. Retail Pharmacies
15.6.4.4.2.2. Hospitals and Clinics
15.6.4.4.2.3. Others
15.6.5. South Africa
15.6.5.1. South Africa Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
15.6.5.1.1. Blood Tests
15.6.5.1.2. Pap Test
15.6.5.1.3. Endometrial Biopsy
15.6.5.1.4. Ultrasound
15.6.5.1.5. Sonohysterography
15.6.5.1.6. Hysteroscopy
15.6.5.2. South Africa Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
15.6.5.2.1. Products
15.6.5.2.2. Drugs and Therapies
15.6.5.2.2.1. Surgical Therapies
15.6.5.2.2.1.1. Dilation and Curettage (D and C)
15.6.5.2.2.1.2. Uterine Artery Embolization
15.6.5.2.2.1.3. Focused Ultrasound Surgery
15.6.5.2.2.1.4. Myomectomy
15.6.5.2.2.1.5. Endometrial Ablation
15.6.5.2.2.1.6. Endometrial Resection
15.6.5.2.2.1.7. Hysterectomy
15.6.5.2.2.2. Non-Surgical Therapies
15.6.5.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
15.6.5.2.2.2.2. Tranexamic Acid
15.6.5.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
15.6.5.2.2.2.4. Oral Contraceptives
15.6.5.2.2.2.5. Oral Progesterone
15.6.5.2.2.2.6. Others
15.6.5.2.3. Menstrual Flow Tracking Applications
15.6.5.3. South Africa Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
15.6.5.3.1. Endometrial Polyps
15.6.5.3.2. Polycystic Ovary Syndrome (PCOS)
15.6.5.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
15.6.5.3.4. Ectopic Pregnancy
15.6.5.3.5. Uterine Fibroids
15.6.5.3.6. Cancer
15.6.5.3.7. Other Diseases and Conditions
15.6.5.4. South Africa Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.6.5.4.1. Online
15.6.5.4.2. Offline
15.6.5.4.2.1. Retail Pharmacies
15.6.5.4.2.2. Hospitals and Clinics
15.6.5.4.2.3. Others
15.6.6. Rest of Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
15.6.6.1.1. Blood Tests
15.6.6.1.2. Pap Test
15.6.6.1.3. Endometrial Biopsy
15.6.6.1.4. Ultrasound
15.6.6.1.5. Sonohysterography
15.6.6.1.6. Hysteroscopy
15.6.6.2. Rest of Middle East & Africa Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
15.6.6.2.1. Products
15.6.6.2.2. Drugs and Therapies
15.6.6.2.2.1. Surgical Therapies
15.6.6.2.2.1.1. Dilation and Curettage (D and C)
15.6.6.2.2.1.2. Uterine Artery Embolization
15.6.6.2.2.1.3. Focused Ultrasound Surgery
15.6.6.2.2.1.4. Myomectomy
15.6.6.2.2.1.5. Endometrial Ablation
15.6.6.2.2.1.6. Endometrial Resection
15.6.6.2.2.1.7. Hysterectomy
15.6.6.2.2.2. Non-Surgical Therapies
15.6.6.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
15.6.6.2.2.2.2. Tranexamic Acid
15.6.6.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
15.6.6.2.2.2.4. Oral Contraceptives
15.6.6.2.2.2.5. Oral Progesterone
15.6.6.2.2.2.6. Others
15.6.6.2.3. Menstrual Flow Tracking Applications
15.6.6.3. Rest of Middle East & Africa Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
15.6.6.3.1. Endometrial Polyps
15.6.6.3.2. Polycystic Ovary Syndrome (PCOS)
15.6.6.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
15.6.6.3.4. Ectopic Pregnancy
15.6.6.3.5. Uterine Fibroids
15.6.6.3.6. Cancer
15.6.6.3.7. Other Diseases and Conditions
15.6.6.4. Rest of Middle East & Africa Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.6.6.4.1. Online
15.6.6.4.2. Offline
15.6.6.4.2.1. Retail Pharmacies
15.6.6.4.2.2. Hospitals and Clinics
15.6.6.4.2.3. Others
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Diagnosis Type
15.7.3. By Offering
15.7.4. By Conditions
15.7.5. By Distribution Channel
16. Latin America Heavy Menstrual Bleeding (HMB) Market Analysis and Forecasts, 2020 - 2028
16.1. Overview
16.1.1. Latin America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn)
16.2. Latin America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
16.2.1. Blood Tests
16.2.2. Pap Test
16.2.3. Endometrial Biopsy
16.2.4. Ultrasound
16.2.5. Sonohysterography
16.2.6. Hysteroscopy
16.3. Latin America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
16.3.1. Products
16.3.2. Drugs and Therapies
16.3.2.1. Surgical Therapies
16.3.2.1.1. Dilation and Curettage (D and C)
16.3.2.1.2. Uterine Artery Embolization
16.3.2.1.3. Focused Ultrasound Surgery
16.3.2.1.4. Myomectomy
16.3.2.1.5. Endometrial Ablation
16.3.2.1.6. Endometrial Resection
16.3.2.1.7. Hysterectomy
16.3.2.2. Non-Surgical Therapies
16.3.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
16.3.2.2.2. Tranexamic Acid
16.3.2.2.3. Hormone-releasing Intrauterine Device (IUD)
16.3.2.2.4. Oral Contraceptives
16.3.2.2.5. Oral Progesterone
16.3.2.2.6. Others
16.3.3. Menstrual Flow Tracking Applications
16.4. Latin America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
16.4.1. Endometrial Polyps
16.4.2. Polycystic Ovary Syndrome (PCOS)
16.4.3. Salpingitis/Pelvic Inflammatory Disease (PID)
16.4.4. Ectopic Pregnancy
16.4.5. Uterine Fibroids
16.4.6. Cancer
16.4.7. Other Diseases and Conditions
16.5. Latin America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
16.5.1. Online
16.5.2. Offline
16.5.2.1. Retail Pharmacies
16.5.2.2. Hospitals and Clinics
16.5.2.3. Others
16.6. Latin America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
16.6.1.1.1. Blood Tests
16.6.1.1.2. Pap Test
16.6.1.1.3. Endometrial Biopsy
16.6.1.1.4. Ultrasound
16.6.1.1.5. Sonohysterography
16.6.1.1.6. Hysteroscopy
16.6.1.2. Brazil Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
16.6.1.2.1. Products
16.6.1.2.2. Drugs and Therapies
16.6.1.2.2.1. Surgical Therapies
16.6.1.2.2.1.1. Dilation and Curettage (D and C)
16.6.1.2.2.1.2. Uterine Artery Embolization
16.6.1.2.2.1.3. Focused Ultrasound Surgery
16.6.1.2.2.1.4. Myomectomy
16.6.1.2.2.1.5. Endometrial Ablation
16.6.1.2.2.1.6. Endometrial Resection
16.6.1.2.2.1.7. Hysterectomy
16.6.1.2.2.2. Non-Surgical Therapies
16.6.1.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
16.6.1.2.2.2.2. Tranexamic Acid
16.6.1.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
16.6.1.2.2.2.4. Oral Contraceptives
16.6.1.2.2.2.5. Oral Progesterone
16.6.1.2.2.2.6. Others
16.6.1.2.3. Menstrual Flow Tracking Applications
16.6.1.3. Brazil Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
16.6.1.3.1. Endometrial Polyps
16.6.1.3.2. Polycystic Ovary Syndrome (PCOS)
16.6.1.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
16.6.1.3.4. Ectopic Pregnancy
16.6.1.3.5. Uterine Fibroids
16.6.1.3.6. Cancer
16.6.1.3.7. Other Diseases and Conditions
16.6.1.4. Brazil Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
16.6.1.4.1. Online
16.6.1.4.2. Offline
16.6.1.4.2.1. Retail Pharmacies
16.6.1.4.2.2. Hospitals and Clinics
16.6.1.4.2.3. Others
16.6.2. Argentina
16.6.2.1. Argentina Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
16.6.2.1.1. Blood Tests
16.6.2.1.2. Pap Test
16.6.2.1.3. Endometrial Biopsy
16.6.2.1.4. Ultrasound
16.6.2.1.5. Sonohysterography
16.6.2.1.6. Hysteroscopy
16.6.2.2. Argentina Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
16.6.2.2.1. Products
16.6.2.2.2. Drugs and Therapies
16.6.2.2.2.1. Surgical Therapies
16.6.2.2.2.1.1. Dilation and Curettage (D and C)
16.6.2.2.2.1.2. Uterine Artery Embolization
16.6.2.2.2.1.3. Focused Ultrasound Surgery
16.6.2.2.2.1.4. Myomectomy
16.6.2.2.2.1.5. Endometrial Ablation
16.6.2.2.2.1.6. Endometrial Resection
16.6.2.2.2.1.7. Hysterectomy
16.6.2.2.2.2. Non-Surgical Therapies
16.6.2.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
16.6.2.2.2.2.2. Tranexamic Acid
16.6.2.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
16.6.2.2.2.2.4. Oral Contraceptives
16.6.2.2.2.2.5. Oral Progesterone
16.6.2.2.2.2.6. Others
16.6.2.2.3. Menstrual Flow Tracking Applications
16.6.2.3. Argentina Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
16.6.2.3.1. Endometrial Polyps
16.6.2.3.2. Polycystic Ovary Syndrome (PCOS)
16.6.2.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
16.6.2.3.4. Ectopic Pregnancy
16.6.2.3.5. Uterine Fibroids
16.6.2.3.6. Cancer
16.6.2.3.7. Other Diseases and Conditions
16.6.2.4. Argentina Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
16.6.2.4.1. Online
16.6.2.4.2. Offline
16.6.2.4.2.1. Retail Pharmacies
16.6.2.4.2.2. Hospitals and Clinics
16.6.2.4.2.3. Others
16.6.3. Rest of Latin America
16.6.3.1. Rest of Latin America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type
16.6.3.1.1. Blood Tests
16.6.3.1.2. Pap Test
16.6.3.1.3. Endometrial Biopsy
16.6.3.1.4. Ultrasound
16.6.3.1.5. Sonohysterography
16.6.3.1.6. Hysteroscopy
16.6.3.2. Rest of Latin America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Offering
16.6.3.2.1. Products
16.6.3.2.2. Drugs and Therapies
16.6.3.2.2.1. Surgical Therapies
16.6.3.2.2.1.1. Dilation and Curettage (D and C)
16.6.3.2.2.1.2. Uterine Artery Embolization
16.6.3.2.2.1.3. Focused Ultrasound Surgery
16.6.3.2.2.1.4. Myomectomy
16.6.3.2.2.1.5. Endometrial Ablation
16.6.3.2.2.1.6. Endometrial Resection
16.6.3.2.2.1.7. Hysterectomy
16.6.3.2.2.2. Non-Surgical Therapies
16.6.3.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
16.6.3.2.2.2.2. Tranexamic Acid
16.6.3.2.2.2.3. Hormone-releasing Intrauterine Device (IUD)
16.6.3.2.2.2.4. Oral Contraceptives
16.6.3.2.2.2.5. Oral Progesterone
16.6.3.2.2.2.6. Others
16.6.3.2.3. Menstrual Flow Tracking Applications
16.6.3.3. Rest of Latin America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Conditions
16.6.3.3.1. Endometrial Polyps
16.6.3.3.2. Polycystic Ovary Syndrome (PCOS)
16.6.3.3.3. Salpingitis/Pelvic Inflammatory Disease (PID)
16.6.3.3.4. Ectopic Pregnancy
16.6.3.3.5. Uterine Fibroids
16.6.3.3.6. Cancer
16.6.3.3.7. Other Diseases and Conditions
16.6.3.4. Rest of Latin America Heavy Menstrual Bleeding (HMB) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
16.6.3.4.1. Online
16.6.3.4.2. Offline
16.6.3.4.2.1. Retail Pharmacies
16.6.3.4.2.2. Hospitals and Clinics
16.6.3.4.2.3. Others
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Diagnosis Type
16.7.3. By Offering
16.7.4. By Conditions
16.7.5. By Distribution Channel
17. Competitive Benchmarking
17.1. Market Share Analysis, 2021
17.2. Global Presence and Growth Strategies
17.2.1. Mergers and Acquisitions
17.2.2. Product Launches
17.2.3. Investments Trends
17.2.4. R&D Initiatives
18. Player Profiles
18.1. Bayer
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. Clue by Biowink GmbH
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. Ferring Pharmaceuticals.
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. Lannett
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. LGM Pharma.
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. Myovant Sciences Ltd.
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. Neurocrine Biosciences, Inc.
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. ObsEva
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. Pfizer Inc.
18.9.1. Company Details
18.9.2. Company Overview
18.9.3. Product Offerings
18.9.4. Key Developments
18.9.5. Financial Analysis
18.9.6. SWOT Analysis
18.9.7. Business Strategies
18.10. RAJVI ENTERPRISE
18.10.1. Company Details
18.10.2. Company Overview
18.10.3. Product Offerings
18.10.4. Key Developments
18.10.5. Financial Analysis
18.10.6. SWOT Analysis
18.10.7. Business Strategies
18.11. The Flex Company
18.11.1. Company Details
18.11.2. Company Overview
18.11.3. Product Offerings
18.11.4. Key Developments
18.11.5. Financial Analysis
18.11.6. SWOT Analysis
18.11.7. Business Strategies
18.12. Thinx, Inc.
18.12.1. Company Details
18.12.2. Company Overview
18.12.3. Product Offerings
18.12.4. Key Developments
18.12.5. Financial Analysis
18.12.6. SWOT Analysis
18.12.7. Business Strategies
18.13. Vibcare Pharma Pvt. Ltd.
18.13.1. Company Details
18.13.2. Company Overview
18.13.3. Product Offerings
18.13.4. Key Developments
18.13.5. Financial Analysis
18.13.6. SWOT Analysis
18.13.7. Business Strategies
18.14. Other Market Participants
19. Key Findings
Note: This
ToC is tentative and can be changed according to the research study conducted
during the course of report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
